How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

346 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation

, St.John's wort, tenofovir, tipranavir, trazodone, vinblastine) Contraindication to MRI Pregnancy, breast-feeding or having a plan to be pregnant Participation in the other investigational drug trials simultaneously or within 3 months before the first administration of the study medication. Observational studies without an intervention (eg study medication) are allowed. Any clinical conditions (eg abnormal lab tests) unsuitable for undergoing clinical trials at the discretion of the clinical

2018 Clinical Trials

82. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014. Full Text available with Trip Pro

patients with available resistance data during LPV/r treatment, 27(42.3%) carried DRM to protease-inhibitor, 28 (58.3%) to reverse-transcriptase-inhibitors and 21 (43.7%) to non-reverse-transcriptase-inhibitors. Darunavir/ritonavir, atazanavir-ritonavir and tipranavir/ritonavir presented the highest susceptibility and nelfinavir the lowest.A better lymphocyte recovering occurred when protease-inhibitor was taken as part of a first-line regimen and a higher number of patients reached viral suppression

2017 PLoS ONE

86. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

NVP nevirapine OST opioid substitution therapy PCr polymerase chain reaction PI protease inhibitor PICO Population, Intervention, Comparison and Outcomes PCP/PJP Pneumocystis (jirovecii) pneumonia PMTCT prevention of mother-to-child transmission of HIV PrEP pre-exposure prophylaxis of HIV rAL raltegravir r BV ribavirin rIF rifampicin r NA ribonucleic acid rTV ritonavir sd-NVP single-dose nevirapine TAM thymidine analogue mutation TB tuberculosis TDF tenofovir disoproxil fumarate TPV tipranavir

2013 World Health Organisation HIV Guidelines

87. Tropical Travel Trouble 009 Humongous HIV Extravaganza

) or Cobicistat is frequently used, The small “r” depicted as a ‘r’ on the end of the 3 letter abbreviations for drugs used can signal ritonavir (i.e. DRV/r) Atazanavir (ATV) Darunavir (DRV) Fos-Amprenavir Lopinavir (LPV) Saquinavir (SAQ) Tipranavir (TPV) Integrase Inhibitors. Blocks the viral DNA integrating into the host’s DNA. Raltegravir (RAL) Elvitegravir (EVG) Dolutegravir (DTG) Bictegravir (BIC) Fusion inhibitors: Attachment inhibitors (CCR5): Fixed dose combinations (not a complete list): Dual

2018 Life in the Fast Lane Blog

88. Antiepileptic drug selection for people with hiv/aids

interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus . 24. Okulicz JF , Grandits GA , French JA , et al . Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study . Bates DE , Herman RJ . Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir . 26. Bonora S , Calcagno A , Fontana S , et al . Clinically significant drug interaction between tipranavir-ritonavir

2012 American Academy of Neurology

89. The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

, quinidine, and pyrimethamine) Riociguat (guanylate cyclase stimulant) Alpha blockers Nitrates (e.g. oral nitrates, sublingual nitroglycerine and nitroglycerine patches) Potent CYP3A4 inhibitors (e.g. clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir) All antihypertensive medications Medications associated with weight changes Drugs approved for the treatment of obesity Cypropheptadine

2017 Clinical Trials

90. Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

. Treatment with acyclovir/valacyclovir is permitted. Use of medications which are associated with Torsade de Pointes. Current or prior history of etravirine (ETR) use. Current use of tipranavir/ritonavir or fosamprenavir/ritonavir. Subjects receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research

2017 Clinical Trials

91. Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

, tipranavir, verapamil, and valspodar). Potential DDI with enzalutamide: strong cytochrome P450 2C8 (CYP2C8) inducers (eg, rifampin), strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifabutin and rifapentine), moderate CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil and nafcillin), and substrates of CYP3A4 (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (eg, phenytoin), or CYP2C19 (eg, S

2017 Clinical Trials

92. Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

phenobarbitone 5 weeks prior to registration. Patients must stop taking all strong CYP3A4 inhibitors, including clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir, prior to registration. Patients must not be planning to receive any concurrent cytotoxic chemotherapy, surgery or radiation therapy during protocol treatment. Use of any prohibited concomitant medications within 7 days of registration

2017 Clinical Trials

93. A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

of the investigator and the sponsor. Gastrointestinal disorder affecting absorption. Current or anticipated use within 7 days prior to first dose of study drug or anticipated use during the study of the following P gp inhibitors (amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, verapamil, and valspodar). Any other acute or chronic

2017 Clinical Trials

94. Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

HCV Genotype 1, 2, 3, 4, 5 or 6 Otherwise eligible for lung transplant at study site Exclusion Criteria: Age <18 Treatment with any of the following agents: Amiodarone. Subjects previously treated with amiodarone must have stopped the amiodarone at least 60 days prior to day 1 SOF/VEL Carbamazepine, phenytoin, phenobarbital, oxcarbazepine Rifabutin, rifampin or rifapentine HIV regimens containing tenofovir or tipranavir/ritonavir St John's wort PPIs, including: Omeprazole, pantoprazole

2017 Clinical Trials

95. Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART

-containing preparations such as cough syrups, tonics etc. Current use of tipranavir or Maraviroc Current use of zidovudine, stavudine or didanosine (as disulfiram potentially has potent irreversible inhibitory effects on mitochondrial metabolism and hence could exacerbate the toxicity of these drugs) Concurrent use of rivaroxaban (a CYP3A metabolized medication) as the cytochrome P450 inhibitory effects of disulfiram on rivaroxaban are unknown Current use of warfarin Individuals who intend to modify

2017 Clinical Trials

96. Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b

. John's Wort (Hypericum perforatum), Glibenclamid, Glyburide, Gemfibrozil, Eltrombopag, Lapatinib, Efavirenz, Atazanavir, Darunavir, Lopinavir, Saquinavir, Tipranavir, Cyclosporine, Simvastatin, Fluvastatin, Rosuvastatin greater than 10 mg dose, Atorvastatine greater than 10 mg dose, hepatotoxic drugs. Any condition that requires administration of systemic corticosteroids, TNF antagonists, or other immunosuppressant drugs during the course of the study. Contacts and Locations Go to Information from

2017 Clinical Trials

97. A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment

and grazoprevir Hypersensitivity to sofosbuvir (genotype 3 infected-participants ony) Currently being treated with an inhibitor of organic anion transporting polypeptide 1B, e.g. rifampicin, atazanavir, daruavir, lopinavir, saquinavir, tipranavir, cobicistat or ciclosporin. Currently being treated with inducers of cytochrome P450 3A or P-glycoprotein, such as efavirenz, phenytoin, carbamazepine, bosentan, etravirine, modafinil or St John's Wort (Hypericum perforatum) Currently being treated with amiodarone

2017 Clinical Trials

98. Treatment Outcomes of Third-Line Antiretroviral Regimens in HIV-Infected Thai Adolescents. (Abstract)

Treatment Outcomes of Third-Line Antiretroviral Regimens in HIV-Infected Thai Adolescents. Efficacy and safety data of third-line antiretroviral (ARV) regimens in adolescents are limited.This study enrolled HIV-infected Thais who were treated with third-line regimens consisting of darunavir/ritonavir (DRV/r), etravirine (ETR), tipranavir/ritonavir or raltegravir.Fifty-four adolescents 2-17 years of age were enrolled from 8 sites and followed for 48 weeks. Reasons for switch were second-line (...) and included ETR/DRV/r (43%), DRV/r (33%), ETR (17%), tipranavir/ritonavir (2%) or raltegravir/DRV/r/ (4%). The median CD4 (interquartile range) increased from 16% (12-21) at third-line switch to 21% (18-25) and 410 (172-682) to 607 (428-742) cells/mm at 48 weeks (P < 0.001). HIV RNA declined from 3.9 (2.9-4.9) to 1.6 (1.6-3.0) log10 copies/mL (P < 0.001) and 33/50 (66%) had levels <50 copies/mL at 48 weeks. Seventeen (31%) had HIV-RNA ≥1000 copies/mL; about half due to poor adherence; genotyping in 13

2017 Pediatric Infectious Dsease Journal

100. Pityriasis versicolor

drugs that are metabolised by the CYP450. Possible drug interactions include: Antidiabetic drugs — no change in dosing is normally needed, but warn the person to report any unexpected changes in blood glucose levels. There are isolated reports of hypoglycaemia following concurrent use. Antiretroviral drugs — fluconazole increases the levels of nevirapine, ritonavir, and tipranavir. Monitor for signs of increased adverse effects. Avoid doses of fluconazole greater than 200 mg daily. Carbamazepine

2015 NICE Clinical Knowledge Summaries

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>